Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Odense C
Clinical trial register · Denmark

Clinical Trials in Odense C, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Denmark and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2469 matching records held by the registry are in this view. Synced 16 Oct 2026, 03:17 UTC
2469
Studies in scope
all four open statuses
1395
Recruiting now
open to new participants
438
Lead sponsors
across recruiting studies
Top sites
Copenhagen 974 Aarhus 586 Odense 441 Aalborg 384 Herlev 314
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca13 Merck Sharp & Dohme LLC12 Odense University Hospital11 Novartis Pharmaceuticals8 Hoffmann-La Roche7
Site location
Copenhagen974 Aarhus586 Odense441 Aalborg384 Herlev314
All 128 locations
Target enrolment
to

Trials with a site in Odense C

110 of 2469 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Denmark
Start
Not yet open
Alexion Pharmaceuticals, Inc.
Phase 3
1,180
Aarhus, Odense C
2027-11-23
Not yet open
Bristol-Myers Squibb
Phase 3
2,380
Hellerup, Aarhus, Odense C, Copenhagen
2026-12-16
Recruiting
Boehringer Ingelheim
Phase 3
448
Copenhagen, Odense C
2026-07-27
Recruiting
Boehringer Ingelheim
Phase 3
390
Aarhus N, Copenhagen, Odense C
2026-07-10
Recruiting
Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors
NCT07630961Metastatic Pancreatic Ductal Adenocarcinoma (PDAC), Non-small Cell Lung Cancer (NSCLC), HR+/HER2- Ductal Breast Cancer (BC), HR+/HER2- Lobular Breast Cancer (BC)
Drug68Ga-NNS309
Novartis Pharmaceuticals
Phase 1
66
Odense C
2026-06-23
Recruiting
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
NCT07652658Idiopathic Pulmonary Fibrosis (IPF)
AstraZeneca
Phase 2
359
Aarhus, Copenhagen, Hellerup, Odense C
2026-06-11
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
340
Copenhagen, Aarhus Nord, Odense C
2026-05-18
Active, closed
Odense University Hospital
Not applicable
20
Odense C
2026-04-25
Recruiting
Janssen Research & Development, LLC
Phase 3
530
Aarhus C, Esbjerg, Gistrup, Herlev, Hilleroed, Hvidovre, København NV, Odense C
2026-04-21
Recruiting
Incyte Corporation
Phase 3
588
Aalborg, Århus N, Herlev, Køge, Odense C, Vejle
2026-04-09
Recruiting
Incyte Corporation
Phase 3
700
Aalborg, Odense C, Roskilde, Vejle
2026-03-05
Recruiting
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
NCT07288359Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer
DrugsLetrozole·Fulvestrant
Novartis Pharmaceuticals
Phase 1/2
205
Odense C
2025-12-29
Recruiting
Pfizer
Phase 3
800
Odense C, Vejle, Aalborg, Copenhagen
2025-12-11
Recruiting
AstraZeneca
Phase 2
230
Aarhus N, Gistrup, Hvidovre, København Ø, Odense C
2025-12-10
Recruiting
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
NCT07261631Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer
Drug68Ga-NNS309
Novartis Pharmaceuticals
Phase 1
180
Odense C
2025-11-24
Recruiting
Novartis Pharmaceuticals
Phase 3
1,275
Aarhus N, Esbjerg, Glostrup Municipality, Odense C
2025-11-11
Recruiting
AstraZeneca
Phase 2
435
Aalborg, Aarhus N, Hvidovre, Odense C, Roskilde
2025-11-06
Recruiting
Novartis Pharmaceuticals
Phase 1/2
188
Herlev, Odense C, Vejle
2025-10-15
Recruiting
Optimized Expansion of the Implanted Transcatheter Aortic Valve
NCT07042529Aortic Stenosis Disease, Valvular Heart Disease
Ole De Backer
Not applicable
1,010
Aa, Aalborg, Copenhagen, Odense C
2025-10-05
Recruiting
Novo Nordisk A/S
Phase 3
1,280
Copenhagen, Aarhus, Odense C
2025-10-02
Recruiting
AbbVie
Phase 2
140
Aarhus, Odense C, Vejle
2025-09-02
Recruiting
Eli Lilly and Company
Phase 1/2
68
Odense C
2025-07-30
Recruiting
Anne Juul Wikkelsø
Phase 4
1,312
Aarhus, Copenhagen, Herlev, Hillerød, Horsens, Hvidovre, Kolding, Odense C
2025-07-15
Recruiting
Alnylam Pharmaceuticals
Phase 3
1,750
Aarhus N, København Ø, Odense C
2025-07-02
Recruiting
AstraZeneca
Phase 2
987
Aalborg, Aarhus, Esbjerg, Hvidovre, Odense C, Roskilde
2025-06-27
Recruiting
Soren Overgaard
Phase 4
210
Copenhagen NV, Herlev, Odense C
2025-06-09
Recruiting
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
NCT06726148Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer
DrugsRibociclib·Fulvestrant
Novartis Pharmaceuticals
Phase 1/2
280
Copenhagen, Odense C
2025-04-03
Active, closed
Acute Effects of SGLT2 Inhibitor on Kidney Allograft Oxygen Tension
NCT06933355Kidney Transplantation Recipients, Magnetic Resonance Imaging (MRI), Sodium-Glucose Transporter 2 Inhibitors, Non-Diabetic Patients
DrugDapagliflozin
Odense University Hospital
Phase 4
8
Odense C
2025-03-27
Recruiting
Daiichi Sankyo
Phase 3
510
Arhus N, Copenhagen, Odense C
2025-03-27
Recruiting
AstraZeneca
Phase 3
990
Aalborg, Hvidovre, Næstved, Odense C, Vejle
2025-03-25
Recruiting
Esbjerg Hospital - University Hospital of Southern Denmark
Not applicable
165
Esbjerg, Odense C, Svendborg, Vejle
2025-02-26
Recruiting
University of Southern Denmark
Not applicable
120
Odense C
2025-02
Recruiting
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
NCT06564038Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma
DrugsSurovatamig·Acalabrutinib·Vincristine·Doxorubicin
AstraZeneca
Phase 1/2
408
Aalborg, Aarhus N, Copenhagen, Odense C
2025-01-30
By invitation
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
NCT06788509Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes
DrugsJNJ-75348780·JNJ-87801493·JNJ-80948543·Ibrutinib
Janssen Research & Development, LLC
Phase 1
120
Copenhagen, Odense C
2024-12-30
Recruiting
Christian Hassager
Phase 2
282
Copenhagen, Odense C
2024-12-12
By invitation
A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
NCT06679946Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
DrugVutrisiran
Alnylam Pharmaceuticals
Phase 3
700
Aarhus N, København Ø, Odense C
2024-12-03
Recruiting
Odense University Hospital
Not applicable
800
Odense C
2024-11-27
Recruiting
GlaxoSmithKline
Phase 3
750
Aarhus N, Copenhagen, Hvidovre, Odense C
2024-11-26
Active, closed
Odense University Hospital
Phase 2
36
Esbjerg, Odense C
2024-11-04
Recruiting
GlaxoSmithKline
Phase 2
393
Esbjerg, Hvidovre, Odense C
2024-09-27
Active, closed
Boehringer Ingelheim
Phase 3
1,666
Hellerup, Odense C
2024-09-26
Recruiting
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
NCT06393738Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL), Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
DrugGlofitamab
Arvinas Inc.
Phase 1
329
Copenhagen, Odense C
2024-09-05
Not yet open
The Efficacy of PIPAC and Minimally Invasive Radical Resection in High-risk Gastric Cancer Patients.
NCT06295094Gastric Cancer, Chemotherapy, Adjuvant, Peritoneal Metastases, Minimally Invasive Surgical Procedures
DrugsDoxorubicin·Cisplatin
Odense University Hospital
Phase 2
264
Odense C
2024-09
Recruiting
AstraZeneca
Phase 3
1,018
Aalborg, Copenhagen, Odense C, Roskilde
2024-08-07
Active, closed
Merck Sharp & Dohme LLC
Phase 3
686
Copenhagen, Aarhus, Odense C
2024-07-24
Recruiting
Amgen
Phase 3
450
Aalborg, Aarhus N, Copenhagen, Odense C
2024-07-17
Active, closed
Merck Sharp & Dohme LLC
Phase 3
300
Copenhagen, Aarhus, Roskilde, Odense C
2024-07-16
Active, closed
Novo Nordisk A/S
Phase 3
10,000
Hellerup, Aalborg, Aarhus N, Gistrup, Hillerød, København Ø, Odense C, Svendborg
2024-06-25
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,530
Herlev, Aarhus N, Aalborg, Odense C, Sønderborg, Vejle
2024-06-24
Recruiting
AstraZeneca
Phase 3
240
Aarhus N, Copenhagen, Odense C
2024-06-20
Active, closed
Amgen
Phase 3
563
Copenhagen, Herning, Odense C
2024-06-05
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Copenhagen, Odense C
2024-06-05
Recruiting
A Multi-center Investigation of Family Health.
NCT06433349Breast Cancer, Prostate Cancer, Colorectal Cancer, Hematologic Neoplasms
Odense University Hospital
Observational
240
Odense C
2024-05-13
Active, closed
argenx
Phase 3
119
Aarhus, Copenhagen, Odense C
2024-04-16
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Copenhagen, Hillerød, Næstved, Odense C, Vejle
2024-04-14
Recruiting
A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis
NCT06072482Antineutrophil Cytoplasmic Antibody-associated Vasculitis
DrugAvacopan
Amgen
Phase 4
300
Aalborg, Copenhagen, Odense C
2024-02-07
Active, closed
Janssen Research & Development, LLC
Phase 3
838
Aarhus, Odense C, Vejle
2024-01-22
Active, closed
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
NCT06183931Transthyretin Amyloid Cardiomyopathy
DrugCliramitug
Alexion Pharmaceuticals, Inc.
Phase 3
1,181
Aarhus, Copenhagen, Odense C
2024-01-11
Recruiting
Odense University Hospital
Not applicable
80
Aarhus N, Odense C
2024-01-09
Recruiting
Merck Sharp & Dohme LLC
Phase 3
614
Herning, Aalborg, Odense C
2023-12-15
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Aalborg, Koege, Odense C
2023-12-13
Recruiting
Odense University Hospital
Not applicable
2,000
Odense, Odense C
2023-12-01
Recruiting
The Fourth Left Atrial Appendage Occlusion Study
NCT05963698Atrial Fibrillation, Stroke, Ischemic, Systemic Embolism
Hamilton Health Sciences Corporation
Not applicable
4,000
Viborg, Aarhus, Esbjerg, Copenhagen, Hjørring, Odense C
2023-11-30
Active, closed
University of Southern Denmark
Not applicable
5,700
Odense C
2023-10-30
Active, closed
Bristol-Myers Squibb
Phase 3
1,057
Aarhus, Odense C, Copenhagen, Hellerup
2023-10-25
Active, closed
Bristol-Myers Squibb
Phase 3
1,255
Aarhus, Odense C, Hellerup
2023-09-14
Recruiting
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
NCT05878717Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
DrugBelimumab
GlaxoSmithKline
Phase 2/3
300
Aarhus N, Odense C
2023-09-13
Recruiting
Incyte Corporation
Phase 1
570
Copenhagen, Herlev, Odense C, Vejle
2023-07-24
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,089
Copenhagen, Aalborg, Odense C
2023-07-19
Active, closed
Hoffmann-La Roche
Phase 3
2,000
Aalborg, Hellerup, Hvidovre, Odense C, Roskilde, Vejle
2023-06-28
Recruiting
Effects of Percutaneous Transluminal Renal Angioplasty of Atherosclerotic Renal Artery Stenosis in High-Risk Patients.
NCT05834803Renovascular Hypertension, Renovascular Hypertension With Renal Failure, Heart Failure, Renal Artery Stenosis Atherosclerotic
University of Aarhus
Not applicable
80
Aarhus N, Copenhagen, Odense C
2023-06-26
Active, closed
Janssen Research & Development, LLC
Phase 3
614
Aalborg, Aarhus, Copenhagen, Herning, Odense C, Vejle
2023-03-29
Active, closed
Merck Sharp & Dohme LLC
Phase 3
300
Aarhus, Aalborg, Odense C, Vejle
2023-03-16
Active, closed
Identification and Treatment of Alcohol Problems in Primary Care
NCT05916027Alcohol Abuse Alcoholism, General Practice, Screening and Brief Intervention
University of Southern Denmark
Not applicable
19
Odense C
2023-01-01
Active, closed
Hoffmann-La Roche
Phase 3
122
Odense C
2022-09-27
By invitation
Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
NCT04905693Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Progressive Pulmonary Fibrosis
DrugTreprostinil
United Therapeutics
Phase 3
1,850
Aarhus N, Hellerup, Odense C
2022-09-06
Recruiting
Odense University Hospital
Not applicable
254
Odense C
2022-04-20
Recruiting
Novartis Pharmaceuticals
Phase 3
540
Aalborg, Aarhus N, Copenhagen, Odense C
2021-09-20
Active, closed
Janssen Research & Development, LLC
Phase 3
743
Aarhus N, Copenhagen, Odense C
2021-08-19
Recruiting
Merck Sharp & Dohme LLC
Phase 2
355
Copenhagen, Odense C
2021-08-12
Active, closed
AstraZeneca
Phase 3
506
Copenhagen, Herlev, Odense C
2021-06-22
Recruiting
GlaxoSmithKline
Phase 2
37
Odense C
2021-04-16
Active, closed
Loxo Oncology, Inc.
Phase 3
500
Aarhus N, Odense C
2021-04-08
Recruiting
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
NCT04728893Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia
DrugNemtabrutinib
Merck Sharp & Dohme LLC
Phase 2
490
Aarhus N, Aalborg, Roskilde, Odense C
2021-04-05
Active, closed
Novo Nordisk A/S
Phase 3
1,205
Aarhus N, Hvidovre, København NV, Odense C
2021-04-01
Active, closed
Pfizer
Phase 3
841
Aalborg, Vejle, Copenhagen, Herlev, Odense C
2020-12-21
Active, closed
Hoffmann-La Roche
Phase 3
992
Herlev, Næstved, Odense C
2020-10-09
Active, closed
Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors
NCT04140500Solid Tumors, Metastatic Melanoma, Non-small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma
DrugTobemstomig
Hoffmann-La Roche
Phase 1/2
170
København Ø, Odense C
2019-11-11
Active, closed
AstraZeneca
Phase 4
75
Aalborg, Aarhus N, Copenhagen, Hvidovre, Næstved, Odense C, Vejle
2019-10-08
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
466
Odense C, Vejle, Herlev
2019-10-02
Active, closed
Hoffmann-La Roche
Phase 1/2
498
Aarhus N, København Ø, Odense C
2019-08-13
Recruiting
Bristol-Myers Squibb
Phase 2
1,500
Odense C
2019-08-09
Active, closed
Tesaro, Inc.
Phase 3
785
Aalborg, Copenhagen, Herlev, Odense C, Roskilde
2019-07-18
Active, closed
AstraZeneca
Phase 2
247
Odense C
2019-06-25
Active, closed
Novartis Pharmaceuticals
Phase 3
1,882
Glostrup Municipality, Odense C
2018-12-28
Active, closed
AbbVie
Phase 3
1,242
Copenhagen NV, Hvidovre, Roskilde, Odense C
2018-08-28
Active, closed
Hoffmann-La Roche
Phase 3
257
Odense C
2018-08-16
Active, closed
Hoffmann-La Roche
Phase 1/2
211
Aarhus N, København Ø, Odense C
2018-05-08
Active, closed
Janssen Research & Development, LLC
Phase 3
211
Aalborg, Aarhus, Copenhagen, Odense C, Roskilde
2018-04-17
Active, closed
Sanofi
Phase 3
475
Aalborg, Aarhus N, Odense C
2017-12-07
Active, closed
SORT OUT X - Combo Stent Versus ORSIRO Stent
NCT03216733Coronary Heart Disease, Angina Pectoris, Myocardial Infarction
Aarhus University Hospital Skejby
Not applicable
3,148
Aalborg, Aarhus N, Copenhagen, Odense C
2017-06-01
Active, closed
Tesaro, Inc.
Phase 3
733
Aalborg, Copenhagen, Herlev, Odense C
2016-07-11
Active, closed
Eli Lilly and Company
Phase 2
309
Aarhus C, Odense C
2016-05-19
Active, closed
Tesaro, Inc.
Phase 1
729
Copenhagen, Odense C
2016-03-07
Active, closed
AstraZeneca
Phase 3
953
Odense C
2015-11-03
Active, closed
AstraZeneca
Phase 3
1,126
Århus C, Herlev, København Ø, Odense C
2015-11-02
Recruiting
COr Loco-regional Advanced Lung Cancer Treated With Chemo-radiotherapy (COLA)
NCT05258448Cardiac Toxicity, Lung Cancer Stage III, Lung Cancer Stage II, Radiation Toxicity
Odense University Hospital
Observational
100
Odense C
2015-08
Recruiting
A Prospective Danish National Registry of PTRA in Patients With Renovascular Hypertension
NCT02770066Renal Artery Obstruction, Hypertension, Renovascular, Cardiovascular Diseases, Kidney Diseases
University of Aarhus
Observational
160
Aalborg, Aarhus N, Glostrup Municipality, Holbæk, Odense C
2015-01-01
Active, closed
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
NCT02319837Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
DrugsLupron·Eligard·Leuprorelin·Xtandi
Pfizer
Phase 3
1,068
Copenhagen N, Arhus N, Copenhagen, Odense C, Vejle
2014-12-17
Active, closed
Odense University Hospital
Not applicable
100
Odense C
2009-05-01
Rows per page Showing 1–110 of 110
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Danish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 16 October 2026. https://priyalifescience.com/clinical-trials-denmark/city/odense-c

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Denmark and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,469 studies in total at the last sync on 16 Oct 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 110 of those studies with a site in Odense C.

How many clinical trials are recruiting in Odense C?

58 of the 110 studies on this page are recruiting new participants as of the 16 Oct 2026, 03:17 UTC sync. A further 3 have not yet opened recruitment, 46 are active but closed to new participants, and 3 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Odense C), 110 studies
PhaseStudiesRecruitingShare
Phase 3572151.8%
Phase 2151113.6%
Not applicable14912.7%
Phase 1/2857.3%
Phase 1645.5%
Phase 4534.5%
Observational332.7%
Phase 2/3221.8%

Most active sponsors

Lead sponsors with the most studies (Odense C)
Lead sponsorStudiesRecruiting
AstraZeneca138
Merck Sharp & Dohme LLC128
Odense University Hospital116
Novartis Pharmaceuticals87
Hoffmann-La Roche70
Janssen Research & Development, LLC61
Bristol-Myers Squibb41
GlaxoSmithKline44
Amgen32
Boehringer Ingelheim32
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.